Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 921-910-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Apr-Jul 18
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2019
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
Test material
- Reference substance name:
- 2-(carbamoyloxy)propyl N-[(3-{[3,5-bis({5-[({[2-(carbamoyloxy)propoxy]carbonyl}amino)methyl]-1,3,3-trimethylcyclohexyl}methyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]methyl}-3,5,5-trimethylcyclohexyl)methyl]carbamate
- EC Number:
- 921-910-2
- IUPAC Name:
- 2-(carbamoyloxy)propyl N-[(3-{[3,5-bis({5-[({[2-(carbamoyloxy)propoxy]carbonyl}amino)methyl]-1,3,3-trimethylcyclohexyl}methyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]methyl}-3,5,5-trimethylcyclohexyl)methyl]carbamate
- Test material form:
- solid
- Details on test material:
- - Analytical purity: 83.9 g/100g
- Composition of test material, percentage of components: 0.2g/100g water, 13.4g/100g n-butyl acetate, 2.5g/100g 1,2-propanediol, monocarbamate
- Lot/batch No.: 389-48
- Expiration date of the lot/batch: 2019-05-23
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Expiration date of the lot/batch: 23-05-2019
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature
- Stability under test conditions: stable
FORM AS APPLIED IN THE TEST (if different from that of starting material)
- Test substance preparations in corn oil
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Wistar Rat; Crl:WI(Han)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboraories, Research Models and Services, Germany GmbH
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: about 11-12 weeks (male animals), about 10 weeks (female animals)
- Housing: During pre-treatment: Polysulfonate cages Typ 2000P (H-Temp), floor area about 2065 cm2 (610 x 435 x 215 mm); supplied by TECHNIPLAST, Hohenpeißenberg, Germany
During pre-mating, mating, gestation, lactation, males after mating and females after weaning: Polycarbonate cages type III
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24°C
- Humidity (%):45-65%
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12h/12h
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- The test substance was applied as suspension.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analytical verification of the test substance preparations were carried out as separate study at the test faciclity Competence Center Analytics of BASF SE. The study was carried out in compliance with GLP. The stability of the test substance in corn oil over a period of 7 days at room temperature was proven (Project No. 17L00369).
- Duration of treatment / exposure:
- The duration of treatment covered a 2-week premating period and mating period in both sexes, one day post-mating in males, and the entire gestation and lactation period in females up to one day prior to the day of schedule sacrifice of the animals.
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 120 mg/kg bw (total dose)
- Dose / conc.:
- 400 mg/kg bw (total dose)
- Dose / conc.:
- 1 200 mg/kg bw (total dose)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The dose level selection was based on a 14-day range-finding study (10C0437/16C137).
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: conducted at least once daily for any signs of morbidity, pertinent behavioral changes and/or signs of overt toxicity. All animals were checked daily for any abnormal clinical signs before the administration as well as within 2 hours and within 5 hours after the administration.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Detailed clinical observations were performed in all animals prior to the administration period and thereafter at weekly intervals.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weight of male and female parental animals was determined before the start of the administration period in order to randomize the animals. During the administration period body weight was determied on study day 0 and thereafter once a week at the same time of the day (in the morning).
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- food consumption was determined once a week for male and female parental animals.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
OPHTHALMOSCOPIC EXAMINATION: Not specified
HAEMATOLOGY: Yes
- Time schedule for collection of blood: In the morning, blood was taken from the retro-bulbar vanous plexus from fasted animals.
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes
- How many animals: 5 surviving parental males per group at termination and in 5 females with litters per group at PND 14.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: In the morning, blood was taken from the retro-bulbar vanous plexus from fasted animals.
- Animals fasted: Yes
- How many animals: 5 surviving parental males per group at termination and in 5 females with litters per group at PND 14.
URINALYSIS: Not specified
IMMUNOLOGY: Not specified
OTHER:
- A functional observational battery was performed in the first five parental male animals per test group and the first surviving females with litter of all test groups at the end of the administration period. The FOB started with passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests.
- Motor activity (MA) was also measured from 14 pm onwards on the same day as the FOB was performed in the first five parental males and the first five surviving females with litter per group.
- For all females of the pool estrous cycle normality was evaluated before the beginning of the administration. In all parental females, in the premating phase, estrous cycle length and normality was evaluated by preparing vaginal smears during a minimum of 2 weeks prior to premating, mating and throughout cohabitytion until there is evidence of sperm in the vaginal smear. Additionally, on the day of scheduled sacrifice, the estrous status was also determined in all F0 female animals.
- Thyroid hormones: blood samples were taken from all surplus pups per litter at PND 4 as well as one male and one female pup per litter at PND14 by decapitation under isoflurane anesthesia. Additionally blodd samples from all dams at PND 14 and all males at termination were taken by puncturing the retrobulbar venous plexus under isoflurane anesthesia. Blood samples from the adult males and the PND 13 pups were assessed for serum levels for thyroid hormones. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
All parental animals were sacrificed by decapitation under isoflurane anesthesia. The exsanguinated animals were necropsied and assessed by gross pathology, special attention being given to the reproductive organs.
The following weights were determined in all animals sacrificed on schedule:
1. Anesthetized animals (final body weight)
2. Epididymides
3. Ovaries
4. Prostate (ventral and dorsolateral part together, fixed)
5. Seminal vesicles with coagulating glands (fixed)
6. Testes
7. Thyroid glands (with parathyroid glands) (fixed)
8. Uterus (with cervix)
The following weights were determined in 5 animals per sex/test group sacrificed on
schedule (females with litters only, same animals as used for clinical pathological
examinations):
1. Adrenal glands (fixed)
2. Brain
3. Heart
4. Kidneys
5. Liver
6. Spleen
7. Thymus (fixed)
All paired organs were weighed together (left and right).
The following organs or tissues of all parental animals were fixed in in 4% neutral-buffered
formaldehyde or in modified Davidson’s solution:
1. All gross lesions
2. Adrenal glands
3. Aorta
4. Bone marrow (femur)
5. Brain
6. Cecum
7. Cervix
8. Coagulating glands
9. Colon
10. Duodenum
11. Epididymides (modified Davidson’s solution)
12. Esophagus
13. Extraorbital lacrimal glands
14. Eyes with optic nerve (modified Davidson’s solution)
15. Femur with knee joint
16. Heart
17. Ileum
18. Jejunum (with Peyer’s patches)
19. Kidneys
20. Larynx
21. Liver
22. Lungs
23. Lymph nodes (axillary and mesenteric)
24. Mammary gland (male and female)
25. Nose (nasal cavity)
26. Ovaries (modified Davidson’s solution)
27. Oviducts
28. Pancreas
29. Parathyroid glands
30. Pharynx
31. Pituitary gland
32. Prostate gland
33. Rectum
34. Salivary glands (mandibular and sublingual)
35. Sciatic nerve
36. Seminal vesicles
37. Skeletal muscle
38. Spinal cord (cervical, thoracic and lumbar cord)
39. Spleen
40. Sternum with marrow
41. Stomach (forestomach and glandular stomach)
42. Testes (modified Davidson’s solution)
43. Thymus
44. Thyroid glands
45. Trachea
46. Urinary bladder
47. Uterus
48. Vagina
The uteri of all cohabited female F0 parental animals were examined for the presence and number of implantation sites. The uteri of apparently nonpregnant animals or empty uterus horns were placed in 1% ammonium sulfide solutions for about 5 minutes in order to be able to identify early resorptions or implantations (SALEWSKI E (1964)). Then the uteri were rinsed carefully in physiologic salt solution (0.9 % NaCl). When the examinations were completed, the uteri were transferred to the Pathology Laboratory for further processing.
Pups
On PND 13, one selected male and one female pup per litter was sacrificed under isoflurane anesthesia by decapitation. Blood was sampled for determination of thyroid hormone concentrations. Thyroid glands/parathyroid glands were fixed in neutral buffered 4% formaldehyde solution and were transferred to the Pathology Laboratory for possible further processing.
HISTOPATHOLOGY: Yes
Fixation was followed by histotechnical processing and examination by light microscopy.
Special attention was given to the stages of spermatogenesis and histopathology of interstitial testicular cell structure. The organs were trimmed according to the “Revised guides for organ sampling and trimming in rats and mice” (Ruehl-Fehlert et al., 2003; Kittel et al., 2004; Morawietz et al., 2004). A correlation between gross lesions and histopathological findings was attempted. Whenever in the ovary the diagnosis: „no abnormalities detected” was used that implies that all different stages of functional bodies (especially corpora lutea) were present and normal. - Statistics:
- Means, medians, standard deviations and deviation vs control of each test group were calculated for several parameters.
For parameters with bidirectional changes: Non-parametric one-way analysis using KRUSKAL-WALLIS test. If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using WILCOXON-test (twosided) for the hypothesis of equal medians.
For parameters with unidirectional changes: Pairwise comparison of each dose group with the control group using the WILCOXON-test (one-sided) for the hypothesis of equal medians
Throughout the chapter "results", the term "significant" implies that the inter-group differences have attained statistical significance (p 0.05) when compared with the control group.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related alterations of mean body weights were observed for male and female animals of test groups 1-3 (120, 400 and 1200 mg/kg bw/d) when compared to the control group.
The body weight change of test group 3 (1200 mg/mg bw/d) was significantly increased during gestation days 7-14. This isolated increase of body weight change in females at one time point was assessed not related to treatment. It is more likely to be related to the larger mean litter size of 13.6 pubs delivered per dam observed in this test group in comparison to control 11.3 pubs delivered per dam. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Food consumption was significantly increased in males of test group 3 (1200 mg/kg bw/d; 10.3%) on study day 7 during premating as well as in males of test group 3 between study days 0-13 (9.1%). It could not be excluded that this increases of food consumption was treatment-related, however, this alteration was assessed as non-adverse.
Food consumption of the F0 females of test group 3 (1200 mg/kg bw/d) as well as males and females in dose groups 1 and 2 (120 and 400 mg/kg bw/d) was not influenced by the treatment throughout the entire study period. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes among clinical chemistry parameters were observed.
At the end of the administration period in rats of both sexes of test group 2 (400 mg/kg bw/d) and in females of test group 1 (120 mg/kg bw/d) globulin values were significantly increased.
Additionally, in females of test group 2, total protein and albumin values were significantly higher compared to controls. All changes were not dose-dependent and therefore they were regarded as incidental and not treatment-related. - Urinalysis findings:
- not specified
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Deviations from "zero values" were obtained in several rats. However, as most findings were equally distributed between test-substance treated groups and controls, without a doseresponse relationship or occurred in single animals only, these observations were considered as incidental.
The following examinations were performed during FOB and are assessed individually:
- Home cage observations: No test substance-related effects were observed.
- Open field observations: No test substance-related effects were observed.
- Sensorimotor tests/reflexes: No test substance-related effects were observed.
- Quantitative Parameters: No test substance-related effects were observed.
Regarding the overall motor activity as well as the individual intervals of observations, no test substance-related deviations were noted for male and female animals. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- All findings were single observations. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- All findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
The stages of spermatogenesis in the testes of males of the high dose test group were comparable to those of the controls. In high dose females the different stages of functional bodies in the ovaries were present and comparable to the control animals.
The female animal (No. 101), which was not pregnant as well as the male mating partner (No. 001) did not show relevant histopathological findings. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- Estrous cycle data revealed regular cycles in the rearing F1 females of all test groups including the control. The mean estrous cycle duration in the different test groups (0-3) ranged from 3.9 to 4.0 days.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 200 mg/kg bw (total dose)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: highest tested dose (limit dose) wihtout any effects
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test, the oral administration by gavage of the test item to Wistar rats revealed no adverse findings in parental animals and progeny up
to 1200 mg/kg bw/d corresponding to 1007 mg/kg bw/d of 3-Isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate, oligomers, reaction products with 1,2-Propanediol, monocarbamate.
Thus, the no observed adverse effect level (NOAEL) for general systemic toxicity, fertility and reproductive performance was 1200 mg/kg bw/d in both sexes of parental animals.
The NOAEL for developmental toxicity in the F1 progeny was 1200 mg/kg bw/d. - Executive summary:
The test substance was administered daily by gavage as a suspension to groups of 10 male and 10 female Wistar rats (F0 animals) at doses of 0, 120, 400 and 1200 mg/kg body weight/day (mg/kg bw/d). The content of the main test compound is 83.9 %, corresponding to 3 -Isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate, oligomers, reaction products with 1,2-propanediol, monocarbamate. Therefore, the dose levels of the test substance correspond to the administration of 0, 101, 336, and 1007 mg/kg bw/d of the four main components. Control animals were dosed daily with the vehicle only (corn oil Ph.Eur.8.0).
The duration of treatment covered a 2-week premating period and mating period in both sexes, (mating pairs were from the same dose group), one day post-mating in males, and the entire gestation and lactation period in females up to one day prior to the day of schedule sacrifice of the animals.
Under the conditions of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test, the oral administration by gavage of the test item to Wistar rats revealed no adverse findings in parental animals and progeny up to 1200 mg/kg bw/d corresponding to 1007 mg/kg bw/d of 3-Isocyanatomethyl-3,5,5 -trimethylcyclohexyl isocyanate, oligomers, reaction products with 1,2-Propanediol, monocarbamate.
Thus, the no observed adverse effect level (NOAEL) for general systemic toxicity, fertility and reproductive performance was 1200 mg/kg bw/d in both sexes of parental animals. The NOAEL for developmental toxicity in the F1 progeny was 1200 mg/kg bw/d.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.